Last week saw a large number of broker notes hitting the wires once again. Three buy ratings that caught my eye are summarised below.
Here's why brokers think investors ought to buy them next week:
Aristocrat Leisure Limited (ASX: ALL)
According to a note out of UBS, its analysts have retained their buy rating and $29.60 price target on this gaming technology company's shares. The broker notes that an industry survey shows that Aristocrat's gaming machine sales fell less than expected during the June quarter. It also shows that its games are in demand, with three out of the top five premium leased machines belonging to Aristocrat. Though, it has warned that its second half earnings could underwhelm due to casino closures. I agree with UBS and believe Aristocrat Leisure would be a great long term investment option.
Corporate Travel Management Ltd (ASX: CTD)
A note out of Ord Minnett reveals that its analysts have upgraded this corporate travel company's shares to a buy rating with an improved price target of $12.97. According to the note, Ord Minnett believes it has more than enough liquidity to ride out the pandemic. It notes that this is a luxury that many of its competitors do not have. In light of this, the broker appears to believe Corporate Travel Management could come out of the crisis in a stronger position. Although I think Ord Minnett makes some great points, I intend to wait for the crisis to pass before considering an investment.
CSL Limited (ASX: CSL)
Another note out of UBS reveals that its analysts have retained their buy rating and $331.00 price target on this biotherapeutics company's shares ahead of its full year results in August. According to the note, the broker expects CSL to deliver a 15% increase in profit in FY 2020. And while it notes that CSL is facing headwinds in FY 2021, it appears optimistic that its vaccine sales will offset some of this. I agree with UBS on this one as well and would be a buyer of its shares.
